InvestorsHub Logo
Followers 2
Posts 245
Boards Moderated 0
Alias Born 08/07/2012

Re: None

Sunday, 03/19/2017 6:35:33 PM

Sunday, March 19, 2017 6:35:33 PM

Post# of 797
Array BioPharma Provides NEMO Update
- NRAS-mutant melanoma NDA withdrawn based on thorough discussions with FDA and following late cycle review meeting -
- Ongoing binimetinib clinical studies will continue; withdrawal will not impact planned COLUMBUS NDA submission of binimetinib, in combination with encorafenib, for BRAF-mutant melanoma expected in mid-2017 -
- See more at: http://investor.arraybiopharma.com/phoenix.zhtml?c=123810&p=irol-newsArticle&ID=2255017#sthash.Y9kiJsug.dpuf
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ARRY News